Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
09/28/2007
Trade Name:
Lamisil Oral Granules
Generic Name or Proper Name (*):
terbinafine
Indications Studied:
Tinea capitis
Label Changes Summary:
New indication in 4 years and older Two randomized safety and efficacy trials were conducted in patients 4 to 12 years old with tinea capitis. Terbinafine was dosed on a mg/kg basis and treated for 6 weeks Although no hepatotoxicity was seen during trials, pre-treatment serum transaminases tests are advised. The most common adverse events observed in the trials were nasopharyngitis, headache, pyrexia, cough, vomiting, and upper respiratory tract infection New 125 mg and 187.5 mg oral granule formulations developed; take with food Information on dose, PK parameters, AE profile, and instructions for use
Product Labeling:
Labeling
BPCA(B):
B
Sponsor:
Novartis
Pediatric Exclusivity Granted Date:
12/04/2006
NNPS:
FALSE'
Therapeutic Category:
Antifungal, topical
-
-